Aroa Biosurgery Ltd (AU:ARX)
ASX:ARX
ARX Stock Chart & Stats
AU$0.58
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.58
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.35 - AU$0.80
Previous CloseN/A
Volume195.72K
Average Volume (3M)302.12K
Market Cap
AU$200.38M
Enterprise ValueAU$197.37M
Total Cash (Recent Filing)AU$20.71M
Total Debt (Recent Filing)AU$6.14M
Price to Earnings (P/E)―
Beta0.82
Next Earnings
May 31, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding345,476,200
10 Day Avg. Volume330,836
30 Day Avg. Volume302,123
Financial Highlights & Ratios
PEG Ratio0.65
Price to Book (P/B)1.73
Price to Sales (P/S)1.90
P/FCF Ratio-25.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.16Price Target Upside100.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.02
Revenue Forecast (FY)AU$115.42M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained revenue expansion indicates rising clinical adoption and broader distributor penetration, supporting recurring procedure-driven sales. Over a 2-6 month horizon this trend underpins higher utilization, improved fixed-cost absorption and the potential to fund further commercial investment without relying solely on one-off events.
Balance Sheet StrengthHigh equity and low leverage provide durable financial flexibility to fund commercialization, inventory and R&D needs while minimizing refinancing risk. This solvency cushion supports multi-month operating continuity, enables opportunistic investment or M&A, and reduces likelihood of forced capital raises during typical industry cycles.
Improving Operating MarginsStrong gross margins and a move to positive EBITDA signal structural improvements in cost management and pricing power. If maintained, these gains translate into sustainable operating cash flow, greater reinvestment capacity in sales and product development, and a clearer path from top-line growth to durable profitability.
Bears Say
Persistent Losses And Negative Free Cash FlowOngoing net losses paired with negative free cash flow constrain internal funding for growth and capital expenditure. Over months this cash burn raises the probability of external financing or dilution, limits strategic optionality, and puts pressure on management to convert revenue gains into positive operating cash flow.
Negative Return On EquityNegative ROE indicates the company is not currently generating returns on shareholder capital, reducing the long-term attractiveness to equity investors. Until consistent profitability is achieved, capital efficiency will remain a structural weakness that can hinder access to favorable financing and long-term investor confidence.
Fragile ProfitabilityDespite revenue and EBITDA improvement, negative EBIT and net margins show the profit base remains vulnerable to pricing, reimbursement or cost pressures. Durable recovery requires sustained margin expansion; otherwise, small adverse shifts in cost or sales mix could reverse recent operational gains.
Aroa Biosurgery Ltd News
ARX FAQ
What was Aroa Biosurgery Ltd’s price range in the past 12 months?
Aroa Biosurgery Ltd lowest share price was AU$0.35 and its highest was AU$0.80 in the past 12 months.
What is Aroa Biosurgery Ltd’s market cap?
Aroa Biosurgery Ltd’s market cap is AU$200.38M.
When is Aroa Biosurgery Ltd’s upcoming earnings report date?
Aroa Biosurgery Ltd’s upcoming earnings report date is May 31, 2026 which is in 57 days.
How were Aroa Biosurgery Ltd’s earnings last quarter?
Aroa Biosurgery Ltd released its earnings results on Nov 25, 2025. The company reported -AU$0.003 earnings per share for the quarter, missing the consensus estimate of AU$0.01 by -AU$0.013.
Is Aroa Biosurgery Ltd overvalued?
According to Wall Street analysts Aroa Biosurgery Ltd’s price is currently Undervalued.
Does Aroa Biosurgery Ltd pay dividends?
Aroa Biosurgery Ltd does not currently pay dividends.
What is Aroa Biosurgery Ltd’s EPS estimate?
Aroa Biosurgery Ltd’s EPS estimate is <0.01.
How many shares outstanding does Aroa Biosurgery Ltd have?
Aroa Biosurgery Ltd has 345,476,200 shares outstanding.
What happened to Aroa Biosurgery Ltd’s price movement after its last earnings report?
Aroa Biosurgery Ltd reported an EPS of -AU$0.003 in its last earnings report, missing expectations of AU$0.01. Following the earnings report the stock price went up 6.25%.
Which hedge fund is a major shareholder of Aroa Biosurgery Ltd?
Currently, no hedge funds are holding shares in AU:ARX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aroa Biosurgery Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.16 (100.00% Upside)
AU$1.16 (100.00% Upside)
Blogger Sentiment
Bullish
AU:ARX Sentiment 100%
Sector Average 69%
Sector Average 69%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.50%
12-Months-Change
Fundamentals
Return on Equity
-3.80%
Trailing 12-Months
Asset Growth
-1.71%
Trailing 12-Months
Company Description
Aroa Biosurgery Ltd
Aroa Biosurgery Limited, a regenerative medicine company, engages in the developing, manufacturing, and distributing medical devices for wound and tissue repair using extracellular matrix (ECM) technology in the United States and internationally. The company's products include Endoform Natural and Endoform Antimicrobia Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; and Reinforced Bioscaffolds, a surgical product for use in ventral hernia repair and abdominal wall reconstruction. Aroa Biosurgery Limited was incorporated in 2007 and is headquartered in Auckland, New Zealand.
ARX Stock 12 Month Forecast
Average Price Target
AU$1.16
▲(100.00% Upside)
Technical Analysis
Polynovo
―
Cochlear
―
Cyclopharm Limited
―
EMvision Medical Devices Ltd.
―
4DMedical Ltd
―
Options Prices
Currently, No data available
---